Ibrutinib Plus Venetoclax Induces Response as First-Line Treatment for CLL/SLL


The combination treatment produced complete responses in more than half of the patients included in the phase 2 CAPTIVATE study.

The combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) produced a complete response (CR) and complete response with incomplete bone marrow recovery (CRi) rate of 56% to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

The phase 2 CAPTIVATE study (NCT02910583) found similarly high rates of overall survival (OS) and progression-free survival (PFS) with the combination therapy for patients overall and with high-risk features.

“The primary end point was met, with a complete response rate of 56% in patients without deletion(17p),” lead author Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele in Milan, Italy, explained in his presentation of the data. “The complete response [rate] was 55% in the all-treated population, and the overall response rate was 96%.”

The primary analysis focused on the fixed-duration cohort of the CAPTIVATE study, with patients receiving 3 cycles of ibrutinib followed by 12 cycles of ibrutinib plus venetoclax. A total of 159 previously untreated patients with CLL/SLL aged 70 years or younger with an ECOG performance score of 2 or less were enrolled in the trial.

Of the 159 patients enrolled, 147 (92%) completed the 12 cycles of ibrutinib plus venetoclax. The median time on study was 27.9 months (range, 0.8-33.2) with a median treatment duration of 13.8 months (range, 0.5-24.9). The median follow-up was 14.0 months after treatment completion

In patients without del(17p), the CR rate was 56% (95% CI, 48%-64%) with the all-treated population reporting a 55% CR rate. The only exception was observed in the bulky disease category, where patients with bulky disease had a CR rate of 31% (95% CI, 18%-44%).

Further, for patients with bone marrow or peripheral disease, high rates of undetectable minimal residual disease (uMRD) were observed, including in patients with high-risk disease features.

When examining patients at 24 months, those without del(17p) treated with the combination had a 96% PFS rate (95% CI, 91%-98%). For OS, the 24-month rate was 98% (95% CI, 94%-99%) for this patient cohort. The median follow-up time was 27.9 months (range, 0.8-33.2).

The most common any-grade adverse effects (AEs) for the combination treatment were diarrhea (62%), nausea (43%), neutropenia (42%), and arthralgia (33%). Grade 3 or 4 AEs included neutropenia (33%), infections (8%), hypertension (6%), and neutrophil count decrease (5%). Twenty-three percent of patients experienced serious AEs, with only 1 fatal AE observed.

The primary end point of the research was investigator-assessed CR/CRi for patients without del(17p), with key secondary end points focusing on overall response rate, duration of response, uMRD rates, progression-free survival, overall survival, tumor lysis syndrome reduction, and safety.

“All of these results together support the idea of the combination of ibrutinib plus venetoclax as an all-oral, once daily, chemo[therapy]-free, fixed-duration [treatment] that may achieve deep responses and undetectable MRD in a vast majority of patients,” concluded Ghia in his presentation of the data.

This combination therapy is currently being examined in a complementary older population for the randomized phase 3 GLOW study (NCT03462719), results of which are expected soon.


Ghia P, Allan JN, Siddiqi T, et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. J Clin Oncol. 2021;39(suppl 15):7502. doi:10.1200/JCO.2021.39.15_suppl.7502

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content